On February 25, 2019, Theratechnologies acquired Katana Biopharma and its targeted oncology technology platform for $8.1 million. The acquisition is part of the companies’ long-term growth strategy to utilize Katana’s platform to continue development and execute their marketing strategies.
Katana Biopharma is a Montreal based biotech company that engages in the development of targeted oncology drugs.
Theratechnologies Inc., based out of Montreal, is a specialty pharmaceutical company, that addresses medical needs of HIV patients to promote healthy living and improve quality of life.
Osler, Hoskin & Harcourt LLP represented Katana Biopharma with a team led by Nathalie Beauregard (Corporate) that included Alain Fournier (Tax).
Key Contact
Partner, Emerging and High Growth Companies, Montréal
Team
Partner, Tax, Montréal
